Thierry Façon

61.6k total citations · 8 hit papers
458 papers, 21.9k citations indexed

About

Thierry Façon is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Thierry Façon has authored 458 papers receiving a total of 21.9k indexed citations (citations by other indexed papers that have themselves been cited), including 412 papers in Hematology, 219 papers in Molecular Biology and 198 papers in Oncology. Recurrent topics in Thierry Façon's work include Multiple Myeloma Research and Treatments (385 papers), Protein Degradation and Inhibitors (136 papers) and Cancer Treatment and Pharmacology (107 papers). Thierry Façon is often cited by papers focused on Multiple Myeloma Research and Treatments (385 papers), Protein Degradation and Inhibitors (136 papers) and Cancer Treatment and Pharmacology (107 papers). Thierry Façon collaborates with scholars based in France, United States and Spain. Thierry Façon's co-authors include Philippe Moreau, Michel Attal, Jean‐Luc Harousseau, Hervé Avet‐Loiseau, Meletios Α. Dimopoulos, Jesús F. San Miguel, Philippe Casassus, Jean Roy, Pieter Sonneveld and Xavier Leleu and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Thierry Façon

441 papers receiving 21.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

1996 2.0k citations Michel Attal, Philippe Casassus et al. profile →
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

2007 1.1k citations Meletios Α. Dimopoulos, Andrew Spencer et al. profile →
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

2003 699 citations Michel Attal, Thierry Façon et al. profile →
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

2011 571 citations Thierry Façon et al. profile →
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2017 518 citations Philippe Moreau, Jesús F. San Miguel et al. profile →
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

2021 460 citations Meletios Α. Dimopoulos, Philippe Moreau et al. profile →
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

2016 328 citations Xavier Leleu, Lionel Karlin et al. profile →
Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

2020 233 citations Michel Attal, Philippe Moreau et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Thierry Façon

Since Specialization

Citations

This map shows the geographic impact of Thierry Façon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thierry Façon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thierry Façon more than expected).

Fields of papers citing papers by Thierry Façon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thierry Façon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thierry Façon. The network helps show where Thierry Façon may publish in the future.

Co-authorship network of co-authors of Thierry Façon

This figure shows the co-authorship network connecting the top 25 collaborators of Thierry Façon. A scholar is included among the top collaborators of Thierry Façon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thierry Façon. Thierry Façon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Complément de rapport. Comment réformer les financements de la recherche hospitalière par les MERRI du ministère de la Santé et de la Prévention 2024 ·Bulletin de l Académie Nationale de Médecine ·Christian Boîtard, Bruno Clément, Thierry Façon, Yvon Lebranchu, A. Migus, Patrick Netter	1
2	Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI). 2024 ·Journal of Clinical Oncology ·(unknown), Cyrille Hulin, Jérôme Lambert, (unknown), Salomon Manier, Aurore Perrot, Arnaud Jaccard, (unknown), Lionel Karlin, Pascal Godmer, Thomas Chalopin, Borhane Slama, Kamel Laribi, Marie‐Lorraine Chrétien, Mohamad Mohty, Cyrille Touzeau, Philippe Moreau, Hervé Avet‐Loiseau, Jill Corre, Thierry Façon	1
3	Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis 2024 ·Blood Advances ·(unknown), Rajshekhar Chakraborty, Bram Rochwerg, Alissa Visram, Ghulam Rehman Mohyuddin, Christopher P. Venner, Irwindeep Sandhu, Arleigh McCurdy, Thierry Façon, María‐Victoria Mateos, Hira Mian	8
4	Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ). 2024 ·Journal of Clinical Oncology ·Thierry Façon, Meletios Α. Dimopoulos, Xavier Leleu, Meral Beksaç, Luděk Pour, Roman Hájek, Zhuogang Liu, Jiří Minařík, Philippe Moreau, Joanna Romejko‐Jarosińska, Ivan Špıčka, Vladimir Vorobyev, Michèle Cavo, Hartmut Goldschmidt, Thomas G. Martin, Salomon Manier, (unknown), Sandrine Macé, (unknown), Robert Z. Orlowski	3
5	A roadmap towards improving outcomes in multiple myeloma 2024 ·Blood Cancer Journal ·Mohamad Mohty, Thierry Façon, Florent Malard, Jean‐Luc Harousseau	4
6	Isatuximab plus carfilzomib and dexamethasone in patients with early <i>versus</i> late relapsed multiple myeloma: IKEMA subgroup analysis 2023 ·Haematologica ·Thierry Façon, Philippe Moreau, Ross Baker, Chang‐Ki Min, Xavier Leleu, Mohamad Mohty, Lionel Karlin, Nicole M. Armstrong, Christina Tekle, (unknown), Marie‐Laure Risse, Thomas G. Martin	11
7	Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH) 2023 ·PubMed ·Nizar J. Bahlis, Luciano J. Costa, Thierry Façon, Jean‐Luc Harousseau, Salomon Manier, Aurore Perrot, Cyrille Touzeau, Mohamad Mohty	1
8	Effective anti-BCMA retreatment in multiple myeloma 2021 ·Blood Advances ·(unknown), David Beauvais, Ibrahim Yakoub‐Agha, Suman Mitra, Timothy Campbell, Thierry Façon, Salomon Manier	27
9	Case Report: Two Cases of Cryptosporidiosis in Heavily Pretreated Patients With Myeloma 2021 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), (unknown), Émilie Fréalle, Hélène Demarquette, Charles Herbaux, (unknown), (unknown), Zoé Van de Wyngaert, Marie‐Pierre Noël, Thierry Façon, Karine Faure, (unknown), Gareth J. Morgan, Faith E. Davies, S. Alfandari, Claire Bories, Eileen M. Boyle	3
10	Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics 2021 ·British Journal of Haematology ·Simon J. Harrison, Aurore Perrot, Adrían Alegre, David Simpson, (unknown), Andrew Spencer, Sosana Delimpasi, Cyrille Hulin, Kazutaka Sunami, Thierry Façon, Philip Vlummens, Kwee Yong, Frank Campana, (unknown), Sandrine Macé, Marie‐Laure Risse, Helgi van de Velde, Paul G. Richardson	32
11	Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study 2018 ·Clinical Cancer Research ·Clément Bailly, Thomas Carlier, Bastien Jamet, Thomas Eugène, Cyrille Touzeau, Michel Attal, Cyrille Hulin, Thierry Façon, Xavier Leleu, Aurore Perrot, Laurent Garderet, Margaret Macro, Denis Caillot, Philippe Moreau, Françoise Kraeber‐Bodéré, Caroline Bodet‐Milin	20
12	Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001 2017 ·Blood ·Thierry Façon, Sagar Lonial, Brendan M. Weiss, Attaya Suvannasankha, Joseph W. Fay, Bertrand Arnulf, Jainulabdeen J. Ifthikharuddin, Carla de Boer, Jianping Wang, Kaida Wu, Ajai Chari, Suzanne Lentzsch, Jordan M. Schecter, Amrita Krishnan	15
13	Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM ‐003 trial for pomalidomide plus low‐dose dexamethasone 2014 ·British Journal of Haematology ·Gareth J. Morgan, Antonio Palumbo, Sujith Dhanasiri, Dawn Lee, Katja Weisel, Thierry Façon, Michel Delforge, Albert Oriol, Mohamed H. Zaki, Xin Yu, Lars Sternås, Christian Jacques, Ron Akehurst, Fritz Offner, Meletios Α. Dimopoulos	14
14	Overall survival of patients with relapsed and refractory multiple myeloma: adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone vs. high-dose dexamethasone 2014 ·Ghent University Academic Bibliography (Ghent University) ·Gillian Morgan, Jesús F. San Miguel, Sujith Dhanasiri, (unknown), Antonio Palumbo, Thierry Façon, Mohamed H. Zaki, Xiaoyan Yu, Lars Sternås, Christian Jacques, Katja Weisel, Fritz Offner, Meletios Α. Dimopoulos	1
15	Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma 2012 ·Cancer Research ·Jill Corre, (unknown), Nicolas Espagnolle, Benjamin Hébraud, Hervé Avet‐Loiseau, Murielle Roussel, Anne Huynh, Mélanie Gadelorge, Pierre Cordelier, Bernard Klein, Philippe Moreau, Thierry Façon, Jean‐Jacques Fournié, Michel Attal, Philippe Bourin	76
16	Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials 2011 ·Blood ·Peter Fayers, Antonio Palumbo, Cyrille Hulin, Anders Waage, Pierre W. Wijermans, Meral Beksaç, Sara Galimberti, Jean–Yves Mary, Peter Gimsing, Fabian Termorshuizen, Rauf Haznedar, Tommaso Caravita, Philippe Moreau, Ingemar Turesson, Pellegrino Musto, Lotfi Benboubker, M. Ronald Schaafsma, Pieter Sonneveld, Thierry Façon, (unknown)	179
17	Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? 2010 ·Blood ·Hervé Avet‐Loiseau, Florent Malard, L. Campion, Florence Magrangeas, Catherine Sebban, Bruno Lioure, Olivier Decaux, Thierry Lamy, Laurence Legros, Jean‐Gabriel Fuzibet, Mauricette Michallet, Bernadette Corront, Pascal Lenain, Cyrille Hulin, Claire Mathiot, Michel Attal, Thierry Façon, Jean‐Luc Harousseau, Stéphane Minvielle, Philippe Moreau, (unknown)	92
18	Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p) 2010 ·Journal of Clinical Oncology ·Hervé Avet‐Loiseau, Xavier Leleu, Murielle Roussel, Philippe Moreau, Catherine Guérin‐Charbonnel, Denis Caillot, Gérald Marit, Lotfi Benboubker, Laurent Voillat, Claire Mathiot, Brigitte Kolb, Margaret Macro, L. Campion, Marc Wetterwald, Anne‐Marie Stoppa, Cyrille Hulin, Thierry Façon, Michel Attal, Stéphane Minvielle, Jean‐Luc Harousseau	298
19	Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial 2009 ·Journal of Clinical Oncology ·Cyrille Hulin, Thierry Façon, Philippe Rodon, Brigitte Pegourié, Lotfi Benboubker, Chantal Doyen, Mamoun Dib, Gaëlle Guillerm, Bruno César Corrêa Salles, Jean‐Paul Eschard, Pascal Lenain, Philippe Casassus, I Azaïs, Olivier Decaux, Laurent Garderet, Claire Mathiot, Jean Fontan, Ingrid Lafon, J.-M. Virion, Philippe Moreau	266
20	Cytogenetics in multiple myeloma: A multicentre study of 24 patients with t(11;14) (q13;q32) or variant. 1996 ·Blood ·JL Laï, Lucienne Michaux, Nicole Dastugue, Agnès Daudignon, Francis Vasseur, Marc Zandecki, F Bauters, Thierry Façon	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact